IP Library › Granted Patent US 12,195,540
Granted Patent B2
US 12,195,540 · App. 18/153,103 · Granted Jan 14, 2025

Antibodies that bind integrin αvβ8 and uses thereof

Inventors: Stephen L. Nishimura (San Francisco, CA); Anthony Cormier (San Francisco, CA); Saburo Ito (San Francisco, CA); Jianlong Lou (San Francisco, CA); James D. Marks (San Francisco, CA); Yifan Cheng (San Francisco, CA); Melody G. Campbell (San Francisco, CA); Jody L. Baron (San Francisco, CA)
Assignee: The Regents of the University of California
C07K16/2839C07K2317/24C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,540
App. No.
18/153,103
Granted
Jan 14, 2025
Kind
B2
Abstract

Antibodies that bind to αvβ8 are provided.

Claims (16)

1. A method of enhancing an immune response to a viral infection in a human individual, the method comprising administering a sufficient amount of an antibody that specifically binds human αvβ8 to the individual, wherein the antibody comprises:

a heavy chain complementary determining region (HCDR) 1 comprising TFTDYSMH (SEQ ID NO:1) or TFTKYSMH (SEQ ID NO:2);

a HCDR 2 comprising RINTETGEPTFADDERG (SEQ ID NO:3);

a HCDR 3 comprising FYYGRD (S/T) (SEQ ID NO:4);

a light chain complementary determining region (LCDR) 1 comprising KSSQSLLNSRSRKNYLA (SEQ ID NO:5) or KSSQSLLHSRSRKNYLA (SEQ ID NO:6);

a LCDR2 comprising WASTRES (SEQ ID NO:7); and

a LCDR3 comprising KQSYNLLS (SEQ ID NO:8), wherein the antibody comprises one or none of SEQ ID NO: 1 and SEQ ID NO:5, but not both of SEQ ID NO: 1 and SEQ ID NO:5, thereby enhancing an immune response to the viral infection.

2. The method of claim 1 , wherein the HCDR1 comprises SEQ ID NO:2 and the LCDR1 comprises SEQ ID NO:6.

3. The method of claim 1 , wherein the HCDR1 comprises SEQ ID NO:1 and the LCDR1 comprises SEQ ID NO:6.

4. The method of claim 1 , wherein the HCDR1 comprises SEQ ID NO:2 and the LCDR1 comprises SEQ ID NO:5.

5. The method of claim 1 , comprising a heavy chain variable region comprising SEQ ID NO:9.

6. The method of claim 1 , comprising a light chain variable region comprising SEQ ID NO: 10.

7. The method of claim 1 , wherein the antibody is humanized.

8. The method of claim 1 , wherein the antibody is linked to a detectable label.

9. The method of claim 1 , wherein the viral infection is a hepatitis infection.

10. The method of claim 1 , wherein the viral infection is a hepatitis B infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2024
From: NISHIMURA, STEPHEN L.; CORMIER, ANTHONY; ITO, SABURO; LOU, JIANLONG; MARKS, JAMES D.; CHENG, YIFAN; CAMPBELL, MELODY G.; BARON, JODY L.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
Reel/Frame 066737/0221 →
Continuity (4)
Continuation 17151009 · Jan 15, 2021
Provisional Application 62961625 · Jan 15, 2020
Provisional Application 63017868 · Apr 30, 2020
Related Publication 20230279119A1 · Sep 7, 2023
References Cited (12)
US 9845357B2 · Nishimura et al. · 2017 [cited by applicant]
US 11608378B2 · Nishimura · 2023 [cited by examiner]
US 20190218298A1 · Nishimura · 2019 [cited by applicant]
WO 2014165524A2 · 2014 [cited by applicant]
WO 2018064478A1 · 2018 [cited by applicant]
WO 2020051333A1 · 2020 [cited by applicant]
Application No. EP21741129.7, Extended European Search Report, Mailed On Dec. 12, 2023, 7 pages. [cited by applicant]
Application No. PCT/US2021/013720, International Preliminary Report on Patentability, Mailed On Jul. 28, 2022, 6 pages. [cited by applicant]
Application No. PCT/US2021/013720, International Search Report and Written Opinion, Mailed On Mar. 26, 2021, 7 pages. [cited by applicant]
Takasaka et al., Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. JCI Insight. 2018:3(20):e122591. (Year: 2018). [cited by applicant]
Seed et al., Inhibition of Integrin Avβ8-mediated TGF-β Activation with C6d4 Provides Improved Potency and Selectivity vs. General TGF-β Inhibitors For Cancer Immunotheraphy. Journal for Immuno Therapy of Cancer, (Nov. … [cited by applicant]
Reszka-Blanco, et al., Inhibition of Integrin αVβ8 in Combination with Low Dose Radiation Induces Antitumor Effect in Advanced Immune Checkpoint Blockade Refractory Tumor Model, The Journal for ImmunoTherapy of Cancer, … [cited by applicant]